DTM™ SCS Superior pain relief. Proven¹

A therapy inspired by science and proven only on Intellis™ with Overdrive™ battery technology.
View the 12 month RCT highlights

12 month's evidence. A lifetime's difference

DTM™ (differential target multiplexed) spinal cord stimulation (SCS) is a proprietary waveform supported by pre-clinical research and clinical research. Delivered via the Medtronic Intellis™ platform, it can be used to treat patients with chronic, intractable pain.

The latest 12-month RCT results show the effectiveness of DTM™ SCS in reducing back pain compared to conventional SCS.1


Listen to our podcast dedicated to DTMTM SCS

DTM™ SCS is a unique pain relief solution that’s inspired by science. In our podcast, two early adopters of our DTM™ SCS waveform, Dr. Ashish Gulve and Dr. Iris Smet discuss the impact of the therapy on their patients.

Expert panel

Dr. Iris Smet
Anesthesiologist in chronic pain management
Vitaz Hospital, St. Nicholas, Belgium

Dr. Ashish Gulve
Consultant in pain management
James Cook Hospital in Middlesbrough, United Kingdom

Dr Gulve and Dr Smet portraits

Beyond the neuron

Decades of basic science research have expanded the understanding of the role of glial cells in the nervous system, which outnumber neurons 12:1 in the spinal cord.2-8

Toward a new theory

Preclinical research9-10 suggests the ability of DTM™ SCS to impact neuronal-glial cell interaction, expanding the understanding of a new SCS MoA. DTM™ waveform best modulates glial and neuronal gene expression back toward the non-pain state.

Inspired by science

The DTM™ waveform is the first SCS therapy intentionally developed from preclinical science.9

DTM™ SCS Therapy

DTM™ SCS primary and secondary outcomes of the 12 Month RCT results

Proven only on Intellis™  with Overdrive™ battery technology

Learn about Intellis™
Image of the front of Medtronic Intellis with AdaptiveStim

Find out more about DTM™ SCS and the
Intellis™ platform

Contact us

See the device/therapy manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events, If using an MRI SureScanTM device, see the MRI SureScanTM technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.


Fishman M, Cordner H, Justiz R, et al. Twelve-Month results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021;21(8):912-923


Allen NJ, Barres BA. Neuroscience: Glia - more than just brain glue. Nature. 2009 Feb 5;457(7230):675-7


Ruiz-Sauri A, Orduña-Valls JM, Blasco-Serra A, et al.  Glia to neuron ratio in the posterior aspect of the human spinal cord at thoracic segments relevant to spinal cord stimulation. J Anat. 2019 Jul 26


Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009 Jan;10(1):23-36


Scholtz and Woolf. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007 Nov;10(11):1361-8


Guthrie PB, Knappenberger J, Segal M, et al.  ATP released from astrocytes mediates glial calcium waves. J Neurosci. 1999 Jan 15;19(2):520-8


Roitbak AI, Fanardjian VV. Dépolarisation of cortical glial cells in response to electrical stimulation of the cortical surface. Neuroscience. 1981;6(12):2529-37


Agnesi F, Blaha CD, Lin J, Lee KH. Local glutamate release in the rat ventral lateral thalamus evoked by high-frequency stimulation. J Neural Eng. 2010 Apr;7(2):26009


Vallejo R, Kelley CA, Gupta A, et al.  Modulation of neuroglial interactions using differential target multiplexed spinal cord stimulation in an animal model of neuropathic pain. Mol Pain. 2020 Jan-Dec;16:1744806920918057


Cedeño DL, Smith WJ, Kelley CA, Vallejo R. Spinal cord stimulation using differential target multiplexed programming modulates neural cell-specific transcriptomes in an animal model of neuropathic pain. Mol Pain. 2020 Jan-Dec;16:1744806920964360